Muscle strength · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Respiratory function: change in FVC% (mean change from baseline to 12 months) · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
1 finding from 1 review
Overall survival · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in overall survival compared with no treatment (low certainty).
1 finding from 1 review
Adverse events, total · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in adverse events, total compared with no treatment (low certainty).
1 finding from 1 review
Serious adverse events · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in serious adverse events compared with no treatment (low certainty).
1 finding from 1 review
Intervention not reported
ALS Functional Rating Scale (ALSFRS) score at 3 months Scale from: 0 to 40 (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Short‐Form‐36 Health Survey (SF‐36) score at 3 months Scale from: 0 to 100 (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Fatigue Severity Scale score at 3 months Scale from: 0 to 63 (lower is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Manual Muscle Testing score at 3 months Right and left shoulder abduction, elbow flexion and extension, finger abduction and extension, hip flexion, knee flexion and extension, foot dorsiflexion and plantarflexion assessed and graded 0 to 5 Medica... · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Upper extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield an U/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Lower extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield a L/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Adverse effects related to the intervention · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Changes to the ALSFRS‐R scores at 12 months · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Muscle strength · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Changes to FSS at 12 months · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Withdrawals due to adverse events · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
rhIGF‐I, 0.1 mg/kg/day ‐ survival at12 months · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review
Intervention not reported
rhIGF‐I, 0.1 mg/kg/day ‐ change in AALSRS at 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review
Intervention not reported
rhIGF‐I, 0.1 mg/kg/day ‐ change in SIP after 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review
no estimate extracted
156 participants
Low
Intervention not reported
rhIGF‐I, all doses ‐ injection site pain · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review